Introduction
Hepatocellular carcinoma (HCC) is the most common primary malignancy arising within the liver. Worldwide HCC is the fifth most common primary malignancy. HCC is the leading cause of death in patients with cirrhosis in Europe and the United States. Although the incidence of HCC in the United States has been low, both the incidence and the mortality from HCC have been increasing. Clinical outcomes for HCC reflect the potential for invasion, which results in intrahepatic spread and a high rate of recurrence following surgical resection. Thus, an understanding of the molecular mechanisms involved in tumor cell invasion and spread is important, and may lead to more effective therapeutic approaches for HCC. microRNAs (miRNAs) are a group of non-coding RNA that are being increasingly recognized as important players in human cancers [3] . Aberrant expression of specific microRNAs, including miR-21, miR-122, miR-221, miR-222, and miR-125b, has been discovered in human HCC cells [22, 27] . Aberrant expression of miRNAs such as miR-21 and miR-122 alters cellular expression of PTEN and cyclin G1 [10, 22] . However, the contribution of the majority of aberrantly expressed miRNAs in tumor cell behavior in HCC is unknown.
The regulation of the tumor suppressor p53 by miR-125b suggests a potential role for miR-125b in tumor cell behavior [19] . E2F3, a transcription factor involved in cell cycle progression has been also identified as a target of miR-125b [14] . Although de-repression of E2F3 promotes neoplastic growth in tumors in which miR-125b is reduced, such as bladder and breast cancer, the silencing of miR-125b in human HCC indicates the presence of additional mechanisms by which miR-125b may contribute to cancer metastasis [2, 20, 21] . Decreased expression of miR-125b has also been reported in other gastrointestinal and breast cancers [28] . In this study, we investigated the epigenetic regulation of miR-125b in hepatocarcinogenesis with respect to the regulation of the specific target gene which is involved in HCC tumor growth, metastasis, and angiogenesis.
Materials and methods
Human liver tissues and cell lines HCC cell lines HepG2 and PLC/PRF-5 were obtained from ATCC (Manassas, VA) and cultured as recommended by the supplier. HCC tumor and normal control tissues were obtained from BioChain Institute, Inc. (Haywood, CA) and used for microRNA real-time PCR array analysis (Supplementary Table 1 ). Additional 19 paired HCC patients and adjacent non-tumoral liver tissues were obtained from the Bank of Tumor Resources, Cancer Center, Sun Yat-sen University in Guangzhou, China (Supplementary Table 2 ).
Luciferase reporter assay
Intact putative miR-125b recognition sequence from the 3 0 -UTR of placental growth factor (PIGF) (pMIR-PIGF-wt-3 0 -UTR) or with random mutations (pMIR-PIGF-mut-3 0 -UTR) were cloned downstream of the firefly luciferase reporter gene. Luciferase assays were performed 72 h after transfection using the Dual Luciferase Reporter Assay system (Promega, Madison, WI).
RNA isolation, real-time PCR, and Western blots
Total RNA was extracted from cells and tissues using Trizol (Invitrogen, Carlsbad, CA). The miRNome MicroRNA PCR Array Kit was purchased from SBI (System Biosciences, Mountain View, CA) and used for miRNA profiling. Real-time PCR analysis of mRNA and miRNAs was performed as described [22] . Western blot analysis was performed as described previously [22] ; the membranes were blotted with antibodies for PIGF and b-actin (both from Santa Cruz Biotechnology, Santa Cruz, CA).
In vitro proliferation, migration, invasion, and angiogenesis assay Commercial available kits were used for proliferation, migration, invasion [1] , and angiogenesis assay in normal and malignant hepatic cells. Cell migration and invasion index was further normalized with proliferation index under the same conditions to rule out the impact factor of altered cell growth rate.
Statistics
A double-sided Student t-test was performed to compare two groups (p <0.05 was considered significant) unless otherwise indicated.
Please see Supplementary data for more detailed information of this section.
Results

miR-125b is aberrantly expressed in HCC tissues and cell lines
Aberrant expression of selected miRNAs has been observed in HCC. To identify miRNAs that are differentially decreased in expression in tumor tissues, we analyzed miRNA expression in three pairs of HCC tumor and normal liver tissues using SBI miRNome MicroRNA Profiling PCR Array. Among 318 of the 379 human miRNAs detected by this PCR array, the expression of 37 miRNAs was significantly altered relative to normal tissues. Of these, the majority of aberrantly expressed miRNAs were increased in expression. However, the expression of two miRNAs, miR-125b and miR-122 was markedly decreased (<4-fold) in tumor tissues compared to normal tissues (Fig. 1) . The expression of miR-125b was decreased in malignant hepatocytes (HepG2 and PLC/PRF-5) compared to that of normal human hepatocytes (Fig. 2) . By the real time-PCR confirmation, miR-125b expression was decreased by 3-fold or more in all three samples compared with the normal liver tissues (Fig. 2D) Modulation of miR-125b alters cell migration and invasion in HCC cell lines
The ability of cells to migrate into adjacent tissues and invade ECM is a key determinant of tumor progression, spread, and metastases. We began by first verifying the efficacy of transfection and target effects by assessing the expression of mature miR-125b by real-time PCR in HepG2 cells (transfected with miR-125b precursor) as well as normal human hepatocytes with anti-miR-125b inhibitor (Fig. 3A) . Next, we assessed vertical cell migration and cell invasion. Pre-miR-125b decreased cell migration as well as invasion in HepG2 and PLC/PRF-5 HCC cell lines, as well as in human liver cancer derived endothelial cells (T-LECs) when compared to relative controls (Fig. 3B) . These results support a functional role for miR-125b in mediating cell migration and invasion in malignant hepatocytes and hepatic tumors endothelial cells, and provide a mechanism by which down-regulation of miR-125b may contribute to tumor spread.
Inhibition of miR-125b increases HCC growth in vitro
We then assessed cellular proliferation in HepG2, PLC/PRF-5, and T-LEC cell lines. In cells transfected with Pre-miR-125b, there was a reduction in proliferation compared to cells transfected with control Pre-miRNA (Fig. 4A) . Moreover, there was a significant change in anchorage-independent growth following the modulation of Pre-miR-125b (Fig. 4B ). Overexpression of miR-125b in PLC/PRF-5 and T-LECs also significantly increased the fractions of early and late apoptotic cell populations (Fig. 4C ). These observations indicate a role for miR-125b in growth regulation of malignant human hepatic cells.
Identification of PIGF as a target for miR-125b
The target prediction program miRNA Viewer database (http:// cbio.mskcc.org/cgi-bin/mirnaviewer/mirnaviewer.pl) indicated the presence of a highly conserved binding site for miR-125b that is present in the 3 0 -UTR region of PIGF, an angiogenic and survival cytokine in cancer biology. To demonstrate PIGF expression pattern in human HCC, 24 human HCC and matched noncancerous liver tissues were analyzed by immunohistochemistry (Fig. 5A ). The human liver cancer tissue array showed the signal intensity was strong (+++) or positive (++) in 18 out of 24 HCC tissues; whereas the weak (+) or negative (++) signals were seen in only 4 out of 24 samples of HCC tissues. Therefore, the PIGF protein expression was much higher in the HCC tissues as compared with the non-cancerous tissues (p <0.01). We have also checked miR-125b and PIGF expression in six pairs of HCC tumor/control tissues and PIGF is overexpressed in four out of five tumor tissues with reduced expression of miR-125b. PIGF is also significantly up-regulated in malignant hepatocytes and hepatic endothelial cells (Figs. 5B and 6A). Both in vitro and in vivo data analyses have demonstrated that the expression of PIGF is reversely correlated with miR-125b expression (Supplementary Fig. 2A and B). However, no negative correlation could be observed between PIGF expression and HCC patients' survival time after surgery (Supplementary Fig. 2C ). To verify that PIGF is a direct target of miR-125b, we performed studies using luciferase reporter constructs containing the miR-125b recognition sequence (Fig. 6B ) from the 3 0 -UTR of PIGF inserted downstream of the luciferase gene. Transfection with miR-125b precursor decreased the reporter activity in HepG2 HCC cells. However, when these studies were repeated with reporter constructs containing random mutations in the recognition sequence, the effects of reporter deactivation by miR125b precursor were abolished (Fig. 6C ). Moreover, a decrease in PIGF expression occurred in HCC cells and tumor endothelial cells after 2 days incubation with miR-125b precursor. Concomitant with enhanced PIGF expression, there was a decrease of MMP-9 expression, an established downstream mediator in PIGF signaling pathway (Fig. 6D) . Among all the other confirmed targets of miR-125b including E2F3, LIN28B, Mucin 1, Bcl 3, and Bak 1, only E2F3 could be verified in HCC cells (Fig. 6D and Supplementary Fig. 2D ). In contrast, transfection with miR-125a precursor, which is also silenced in HCC tumors and modulates cell growth in malignant hepatocytes, did not alter the expression of PIGF with a relative expression of 1.04 ± 0.11-fold of controls. To evaluate the contribution of PIGF to miR-125b mediated cell invasion and migration, we assessed the impact of PIGF through transient transfection, and hence PIGF expression on miR-125b dependent cell proliferation, migration, and invasion in HepG2, PLC/PRF-5, and T-LEC cells. Co-transfection experiments with wild-type PIGF constructs and Pre-miR-125b are also performed and the recovery effects of PIGF re-introduction on migration inhibition and growth suppression induced by miR-125b are verified ( Supplementary Fig. 3 ). Taken together, these findings indicate that PIGF is a biologically relevant target of miR-125b.
miR-125b expression can be epigenetically regulated
To evaluate for potential mechanisms by which miR-125b expression was deregulated in HCC, we assessed the effect of the methylation inhibitor, 5-Aza-CdR, on miR-125b expression in malignant hepatic cells. The dramatic increases in miR-125b were noted in HepG2 cells and T-LECs compared to relative control after 5-Aza-CdR treatment ( Supplementary Fig. 4A ). We selected 2000 bps of sequence extending from the region of the miR-125b. Analysis of the specific region revealed the presence of CpG islands $300 base pairs close to the miR-125b sequence ( Supplementary Fig. 5 ). These results suggest that the expression of miR-125b could be potentially regulated by the modulation of promoter methylation. Of note, the short arm of chromosome 11 is a ''hot spot'' for hypermethylation in human neoplasia [6] . Thus, we examined the methylation status of a specific region of miR-125b by methylation-specific PCR (MSP), a bisulfite conversion based PCR technique for the study of DNA CpG methylation. Using a real-time MSP assay, we found that the specific region of miR-125b was hypermethylated in HepG2 cells and TLECs, but not normal hepatocytes and LSECs ( Supplementary  Fig. 4B ). Moreover, miR-125b is also epigenetically modified in HCC tissues detected by MSP assay (Supplementary Fig. 6A ). 5-Aza-CdR induced de-methylation of miR-125b CpG islands was also confirmed in HepG2 cells and T-LECs ( Supplementary  Fig. 6B ). These results suggest that gain of the methylation mark in the miR-125b region could be associated with the deactivation of miR-125b expression in HCC cells.
Regulation of angiogenesis by miR-125b in normal and malignant hepatic endothelial cells
Since PIGF is the member of VEGF family and exerts pleiotrophic functions in promoting tumor growth and angiogenesis, we next examined the alterations of angiogenesis following the overexpression of miR-125b in hepatic endothelial cells for 72 h. Significant overexpression of PIGF was observed in T-LECs relative to Control Anti-miRNA Anti-miR-125b
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Control Pre-miRNA Pre-miR-125b LSECs (Fig. 6A) , along with the substantial reduction of miR-125b (Supplementary Fig. 4A ). De-methylation treatment by 5-AzaCdR significantly reduced the angiogenesis index in T-LECs but not LSECs (Supplementary Fig. 4C ). Changes in angiogenesis in T-LECs become apparent as well after 72 h transfection of PremiR-125b, whereas only moderate reductions were noticed in LSECs group (Supplementary Fig. 4D ). Modulation of miR-125b also affected invasion potentials in T-LECs but not in LSECs (Fig. 3D) . Taken together, these results suggest that miR-125b dependent regulation of PIGF contributes to tumor endothelial cell angiogenesis and invasion.
miR-125b regulates matrix metalloproteinase mRNA expression
Invasion through basement membrane and interstitial ECM involves a series of proteolytic enzymes named matrix metalloproteinases. Alterations of the PIGF-VEGF complexes have been mechanistically linked to decreased expression of MMPs and cell invasion [9] . We therefore examined the expression of selected MMPs involved in cell invasion in HCC/normal liver tissues and cell lines. Compared with the expression in the normal liver tissue, the expression of MMP-2 and MMP-9 is increased in HCC tumors (Supplementary Fig. 7A ). Enhanced expression of MMP-2 and MMP-9 was also seen in HepG2 cells and T-LECs compared to normal hepatocytes and LSECs ( Supplementary  Fig. 7B ). To confirm the functional impact and relevance of miR125b dependent modulation of PIGF, we assessed the effect of modulation of miR-125b and de-methylation on MMPs expression. Inhibition of DNA methylation by 5-Aza-CdR significantly up-regulated MMP-2 and MMP-9 expression in hepG2 and T-LEC cells (Supplementary Fig. 7C ). Furthermore, the expression of both MMP-2 and MMP-9 mRNA was significantly reduced after transfection with Pre-miR-125b in HepG2, PLC/PRF-5, and T-LEC cell lines (Supplementary Fig. 7D ). These findings link epigenetic regulator, miR-125b, and putative mediators of cell invasion in malignant hepatic cell lines and suggest that de-regulated expression of miR-125b can contribute to tumor spread.
Discussion
In this study, we demonstrated the role of alterations of miR-125b in contributing to cellular phenotypic changes that are associated with tumor progression. We showed that miR-125b is silenced in malignant hepatocytes and tumor endothelial cells compared to relative normal hepatic cells (controls), and that it may contribute to tumor spread by modulating cell proliferation, migration, invasion, and angiogenesis. Some of these effects are mediated through PIGF, a member of the VEGF sub-family and an important cytokine of cancer cell survival and tumor angiogenesis. Decreased expression of miR-125b was shown by in situ hybridization and PCR analysis in human HCCs and a similar role for miR-125b has been postulated in breast, bladder, as well as head and neck carcinogenesis [2, 15, 17, 18, 20, 21, [26] [27] [28] . The concomitant silencing of miR-125b-dependent activation of metalloproteinases in tumor cells can facilitate tissue invasion. These findings support the oncogenic role for silencing of miR-125b in contributing to the spread of liver cancers. miRNA mediated mechanisms are being increasingly implicated in tumor progression. Deregulation of miR-125b can occur as a result of chemotherapy of cancer patients. Likewise, the ectopic expression of miR-125b can modulate expression of genes that are known to be involved in cancer cell survival such as Bak1, CRaf, E2F3, and Bcl2 modifying factor (BMF) [13, 29, 31] . These and other studies [11, 13, 24 ] support a tumor suppressor role for miR125b. Tumors with low expression of miR-125b lack its pro-apoptotic stimulus and acquire the capability to proliferate and grow. Variable expression of miR-125b has been reported in different organ systems and diseases states. In breast and bladder cancer cells, miR-125b is a potent suppressor of cell proliferation but it supports cell growth in prostate carcinogenesis [25] . These diverse observations necessitate a clear definition of tissue-specific expression and function of miR-125b expression. It is likely that targeted therapeutic approaches involving miR-125b may result from defining tissue and disease-state specific roles of miR-125b.
PIGF is one of the endothelial growth polypeptides with structural similarities to VEGF. It is found to be specifically expressed in the placenta and in some tumor cell types. PIGF is expressed during embryonic vasculogenesis; nevertheless, PIGF is not required for embryonic vessel formation because mice lacking PIGF develop normally. In contrast, PIGF seems to contribute to pathologic angiogenesis. For example, in PIGF-deficient mice, tumor growth and tumor angiogenesis are markedly reduced. Recently, it has been shown that circulating hematopoietic progenitor cells and macrophages contribute to tumor angiogenesis, and that PIGF might induce tumor angiogenesis by the recruitment of these cells to the growing tumors [4] . Overexpression of PIGF has been correlated with early recurrence of HCC, suggesting that PIGF may be an important prognostic indicator in HCC [12, 23] . Moreover, up-regulation of PIGF has been observed in hepatitis C cirrhosis patients [16] .
Our findings identify a previously unrecognized mechanism for direct regulation of PIGF, involving non-coding microRNA in HCC. Epigenetic mechanisms of regulation of expression involving PIGF promoter methylation are well recognized [30] . However, we did not observe a correlation between promoter methylation and reduced PIGF immunoreactivity in human HCC tissues and cells supporting the argument that there may be additional mechanisms. The relationship between miRNA-dependent pathways and other mechanisms of regulation during tumor spread warrants further detailed study. Epigenetically mediated gene silencing through promoter hypermethylation can contribute to cancer initiation and progression [5, 7, 8] . Many studies have shown that CpG island methylation changes can play a significant role in human HCC and other cancers. Genomic scanning approaches to identify epigenetically modified targets in HCC are lacking, but such strategies could identify other novel targets that could be epigenetically modified in HCC.
The current effective treatments available for HCC are only applicable in a relatively small proportion of early stage cases. We postulate that therapeutic strategies based on targeting miR-125b may be useful to consider in the adjuvant setting to limit intrahepatic metastases. The presence of therapeutic strategies targeting miRNA, with diverse mechanisms, makes them interesting starting points in the search for potential strategies for prevention of spread in patients who have undergone resection or locoregional therapies for advanced HCC.
